Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Proc Natl Acad Sci U S A. 1978 May; 75(5): 2416–2420.
doi: 10.1073/pnas.75.5.2416
PMCID: PMC392564
PMID: 276881

Complement C3 convertase: Cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cells

Michael K. Pangburn and Hans J. Müller-Eberhard
Author information Copyright and License information PMC Disclaimer

Abstract

The alternative or properdin pathway of complement is primarily controlled by the endopeptidase C3b inactivator (C3bINA) and the nonproteolytic glycoprotein β1H. The molecular mechanisms of control were investigated by performing binding studies of radiolabeled complement proteins to C3b bearing sheep erythrocytes (ESC3b). C3b was found to have distinct binding sites for β1H, C3bINA, Factor B, and properdin. β1H binding increased C3bINA binding 30-fold, while Factor B binding prevented C3bINA action on C3b and was competitive with β1H binding. Properdin binding, which facilitates Factor B interaction with C3b, had no effect on the β1H and C3bINA sites. Activators such as rabbit erythrocytes (ER) have previously been shown to interfere with the effectiveness of the control by C3bINA and β1H, thereby allowing unrestricted formation of C3 convertase. Such restriction of control does not occur on the surface of ES, a nonactivator of the alternative pathway. On the basis of comparative binding studies, restriction of control is explained entirely by reduced binding of β1H to ERC3b relative to ESC3b. Access of properdin, Factor B, C3bINA, and the Fab fragment of anti-C3 to the two cell types was unrestricted. Restriction of β1H control could be generated on the surface of ES by removal of cell-surface sialic acid with neuraminidase (acylneuraminyl hydrolase; EC 3.2.1.18). This enzymatic treatment converted ES from a nonactivator to an activator of the alternative pathway.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1001K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

 
icon of scanned page 2416
2416
icon of scanned page 2417
2417
icon of scanned page 2418
2418
icon of scanned page 2419
2419
icon of scanned page 2420
2420
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Müller-Eberhard HJ, Götze O. C3 proactivator convertase and its mode of action. J Exp Med. 1972 Apr 1;135(4):1003–1008. [PMC free article] [PubMed] [Google Scholar]
  • Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268–3272. [PMC free article] [PubMed] [Google Scholar]
  • Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med. 1976 Nov 2;144(5):1147–1163. [PMC free article] [PubMed] [Google Scholar]
  • Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977 Jul 1;146(1):257–270. [PMC free article] [PubMed] [Google Scholar]
  • Fearon DT, Austen KF. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683–1687. [PMC free article] [PubMed] [Google Scholar]
  • Fearon DT, Austen KF. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med. 1977 Jul 1;146(1):22–33. [PMC free article] [PubMed] [Google Scholar]
  • Tack BD, Prahl JW. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. [PubMed] [Google Scholar]
  • Götze O, Müller-Eberhard HJ. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed] [Google Scholar]
  • Götze O, Müller-Eberhard HJ. The role of properdin in the alternate pathway of complement activation. J Exp Med. 1974 Jan 1;139(1):44–57. [PMC free article] [PubMed] [Google Scholar]
  • David GS, Reisfeld RA. Protein iodination with solid state lactoperoxidase. Biochemistry. 1974 Feb 26;13(5):1014–1021. [PubMed] [Google Scholar]
  • Bolton AE, Hunter WM. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J. 1973 Jul;133(3):529–539. [PMC free article] [PubMed] [Google Scholar]
  • NISONOFF A, WISSLER FC, LIPMAN LN, WOERNLEY DL. Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch Biochem Biophys. 1960 Aug;89:230–244. [PubMed] [Google Scholar]
  • Schreiber RD, Medicus RG, Gïtze O, Müller-Eberhard HJ. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med. 1975 Sep 1;142(3):760–772. [PMC free article] [PubMed] [Google Scholar]
  • WARREN L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959 Aug;234(8):1971–1975. [PubMed] [Google Scholar]
  • Medicus RG, Götze O, Müller-Eberhard HJ. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med. 1976 Oct 1;144(4):1076–1093. [PMC free article] [PubMed] [Google Scholar]
  • Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268–3272. [PMC free article] [PubMed] [Google Scholar]
  • Schreiber RD, Götze O, Müller-Eberhard HJ. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med. 1976 Oct 1;144(4):1062–1075. [PMC free article] [PubMed] [Google Scholar]
  • Fearon DT, Austen KF. Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3220–3224. [PMC free article] [PubMed] [Google Scholar]
  • PILLEMER L, BLUM L, LEPOW IH, ROSS OA, TODD EW, WARDLAW AC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954 Aug 20;120(3112):279–285. [PubMed] [Google Scholar]
  • Phillips JK, Snyderman R, Mergenhagen SE. Activation of complement by endotoxin: a role for 2 globulin, C1, C4 and C2 in the consumption of terminal complement components by endotoxin-coated erythrocytes. J Immunol. 1972 Aug;109(2):334–341. [PubMed] [Google Scholar]
  • Joseph BS, Cooper NR, Oldstone MB. Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med. 1975 Apr 1;141(4):761–774. [PMC free article] [PubMed] [Google Scholar]
  • Sandberg AL, Oliveira B, Osler AG. Two complement interaction sites in guinea pig immunoglobulins. J Immunol. 1971 Jan;106(1):282–285. [PubMed] [Google Scholar]
  • Lachmann PJ, Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol. 1975 Jul;21(1):109–114. [PMC free article] [PubMed] [Google Scholar]
Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences
-